Source:http://linkedlifedata.com/resource/pubmed/id/15715181
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2005-2-17
|
| pubmed:abstractText |
In addition to breathlessness and cough, excessive mucus production is one of the main symptoms of chronic obstructive pulmonary disease (COPD). Excess mucus coupled with deteriorating mucociliary clearance is associated with a decline in lung function and an increased risk of death from pulmonary infection. The effect of Viozan (Sibenadet HCl, AR-C68397AA), a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist, on mucociliary clearance was investigated together with that of a beta2-adrenoceptor agonist, salbutamol. Using a double blind, parallel group study design, 15 patients with COPD, all habitual smokers, were randomised to receive nebulised sidenadet (3mg tid; n = 7) or salbutamol (5mg tid; n = 8) for 10 days. Lung mucociliary clearance rates were measured, by a standard radioaerosol technique, before and after the treatment period, as were 24-h sputum volumes. Both sibenadet and salbutamol therapies resulted in significant (P<0.02) enhancement of lung mucociliary clearance. The 24-h sputum volume was significantly reduced following sibenadet therapy (P<0.03) whereas salbutamol therapy had no effect. Our results, in addition to illustrating the effects of a standard beta2 agonist on mucociliary clearance, strongly suggest the potential dual benefit of dual-agonist compounds in lessening sputum production whilst simultaneously enhancing mucociliary clearance. For reasons unconnected with the present study, development work on this specific formulation is no Longer proceeding.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0954-6111
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
99
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
145-51
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15715181-Administration, Inhalation,
pubmed-meshheading:15715181-Adrenergic beta-Agonists,
pubmed-meshheading:15715181-Aged,
pubmed-meshheading:15715181-Albuterol,
pubmed-meshheading:15715181-Double-Blind Method,
pubmed-meshheading:15715181-Female,
pubmed-meshheading:15715181-Forced Expiratory Volume,
pubmed-meshheading:15715181-Humans,
pubmed-meshheading:15715181-Male,
pubmed-meshheading:15715181-Middle Aged,
pubmed-meshheading:15715181-Mucociliary Clearance,
pubmed-meshheading:15715181-Peak Expiratory Flow Rate,
pubmed-meshheading:15715181-Pulmonary Disease, Chronic Obstructive,
pubmed-meshheading:15715181-Quality of Life,
pubmed-meshheading:15715181-Risk Factors,
pubmed-meshheading:15715181-Smoking,
pubmed-meshheading:15715181-Sputum,
pubmed-meshheading:15715181-Thiazoles,
pubmed-meshheading:15715181-Treatment Outcome,
pubmed-meshheading:15715181-Vital Capacity
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Mucociliary clearance in COPD can be increased by both a D2/beta2 and a standard beta2 agonists.
|
| pubmed:affiliation |
Department of Medical Physics and Thoracic Medicine, Royal Free and University College Medical School, London, UK. amer.alhasani@royalfree.nhs.uk
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|